Cell therapy to treat mitochondrial diseases

Minovia Therapeutics is pioneering the field of mitochondrial cell therapy, focusing on the therapeutic potential of mitochondria to address mitochondrial dysfunction, which can lead to a variety of health issues ranging from rare diseases to age-related conditions. The company has developed Mitochondrial Augmentation Technology (MAT), an investigational therapy that aims to enrich cells—either autologous or allogeneic—with healthy, functional mitochondria. This innovative approach targets the root causes of mitochondrial diseases, offering a promising therapeutic modality that could be applicable to a wide range of indications associated with mitochondrial dysfunction.

The scientific foundation of Minovia's work is built on a collaborative and multidisciplinary approach, integrating expertise from various fields such as mitochondrial science, molecular biology, and bioinformatics. The company emphasizes the importance of feedback between clinical development and preclinical research, ensuring that patient experiences inform their scientific endeavors. Minovia also engages in partnerships with leading research institutions and experts, such as the MITGEST Consortium and Technion, to advance their understanding of mitochondrial biology and enhance the development of their MAT platform. This commitment to collaboration and innovation positions Minovia Therapeutics as a leader in the quest to transform the treatment landscape for mitochondrial diseases.

Israel

Minovia Therapeutics is a clinical-stage international biotechnology company, established in hopes to bring life changing therapies to patients with Mitochondrial diseases, as fast as responsible.
Following compassionate use cases performed in Sheba Medical hospital in Israel, using our proprietary Mitochondrial Augmentation Therapy, Minovia is now conducting the first of its kind clinical trial for Pearson syndrome, an ultra-rare pediatric disease.

Minovia Therapeutics

Company Details